Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D08LRV
|
|||
Former ID |
DNCL002836
|
|||
Drug Name |
BGP-15
|
|||
Synonyms |
66611-37-8; BGP-15 2HCl; 3-Pyridinecarboximidamide, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-, hydrochloride (1:2); BGP 15; BGP15; SCHEMBL3067994; MolPort-039-099-291; MolPort-027-834-918; s8370; AKOS016007888; AKOS026745444; SB17119; CS-6045; 3-Pyridinecarboximidamide, N-(2-hydroxy-3-(1-piperidinyl)propoxy)-, dihydrochloride; BGP-15, > AS-16983; TC-162219; AX8217132; KB-258115; HY-100828; (Z)-N'-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidamide dihydrochloride
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 2 | [1], [2], [3] | |
Company |
N-Gene Research Laboratories
|
|||
Structure |
Download2D MOL |
|||
Formula |
C14H24Cl2N4O2
|
|||
Canonical SMILES |
C1CCN(CC1)CC(CON=C(C2=CN=CC=C2)N)O.Cl.Cl
|
|||
InChI |
1S/C14H22N4O2.2ClH/c15-14(12-5-4-6-16-9-12)17-20-11-13(19)10-18-7-2-1-3-8-18;;/h4-6,9,13,19H,1-3,7-8,10-11H2,(H2,15,17);2*1H
|
|||
InChIKey |
ISGGVCWFTPTHIX-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 66611-37-8
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Jun N terminal kinase (JNK) | Target Info | Inhibitor | [3] |
Poly [ADP-ribose] polymerase (PARP) | Target Info | Modulator | [1], [2] |
References | Top | |||
---|---|---|---|---|
REF 1 | BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases. Mol Cell Biochem. 2012 Jun;365(1-2):129-37. | |||
REF 2 | BGP-15 - a novel poly(ADP-ribose) polymerase inhibitor - protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem Pharmacol. 2002 Mar 15;63(6):1099-111. | |||
REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.